Anti-Vascular Endothelial Growth Factor Therapeutics Market on Track for Strong Growth, Estimated to Grow at 2.3% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Anti-Vascular Endothelial Growth Factor Therapeutics Market Through 2025?
In recent years, the market size for anti-vascular endothelial growth factor therapeutics has shown a minor increase. It is projected to expand from a value of $12.2 billion in 2024 to $12.31 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 1.0%. Factors contributing to the historical growth include a surge in age-related macular degeneration, a rise in diabetic retinopathy cases, advances in diagnosing retinal disease, clinical successes and effectiveness, as well as a shift towards outpatient treatment.

What's the Projected Size of the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market by 2029?
The market for anti-vascular endothelial growth factor therapeutics is set to experience consistent expansion in the looming years, projecting to reach "$13.49 billion by 2029, with a 2.3% compound annual growth rate (CAGR). This market growth during the predicted timeframe can be linked to factors such as the rise of age-related and ocular diseases, wider use in treating retinal disorders, evolution of next-gen therapeutics, more focus on early-stage interventions, global health drives, and better treatment accessibility. Some key trends to watch during this period are the heightened use in cancer therapies, an emphasis on combined treatments in ophthalmology, investigation into biosimilar variations, studies into resistance pathways, and the incorporation of imaging technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

Top Growth Drivers in the Anti-Vascular Endothelial Growth Factor Therapeutics Industry: What's Accelerating the Market?
The surge in instances of ophthalmic diseases is anticipated to be a primary factor fueling expansion in the therapeutics market for anti-vascular endothelial growth factor. When referring to ophthalmic diseases' prevalence, it means the count or share of individuals in a specific population diagnosed with or displaying particular eye conditions or diseases. Anti-vascular endothelial growth factor (VEGF) treatments function to lower ophthalmic diseases prevalence by successfully addressing conditions including wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. For instance, per the World Health Organization's records from October 2022, it was reported that worldwide, nearly 2.2 billion individuals experience near or distant vision impairment, with 1 billion dealing with near or distant vision handicap. Further details show that around 88.4 million among these have refractive errors, 94 million have cataracts, 8 million have age-related macular degeneration, and approximately 3.9 million are dealing with diabetic retinopathy. As such, the increasing occurrence of ophthalmic diseases propels the expanding anti-vascular endothelial growth factor therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp

What Trends Will Shape the Anti-Vascular Endothelial Growth Factor Therapeutics Market Through 2029 and Beyond?
The anti-vascular endothelial growth factor therapeutics market is seeing the rise of a major trend - innovations in therapeutics. To maintain their market standing, firms in this industry are embracing these revolutionary therapeutics. Take the example of Ashvattha Therapeutics Inc., a clinical-stage biopharmaceutical enterprise in the US. In May 2022, they unveiled phase 1 safety data for healthy candidates for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema), namely D-4517.2 therapy. This first-of-its-kind therapy is designed to cater to the unfulfilled needs associated with DME conditions. The administration of this therapy is designed for patient self-administration through an autoinjector. Utilizing the D-4517.2 autoinjector, patients can easily self-administer the medication once monthly from their home's convenience.

What Are the Main Segments in the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented -

1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users

Subsegments:
1) By Eylea: Indications, Dosage Forms
2) By Lucentis: Indications, Dosage Forms
3) By Beovu: Indications, Dosage Forms

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp

Which Top Companies are Driving Growth in the Anti-Vascular Endothelial Growth Factor Therapeutics Market?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

Which Regions Will Dominate the Anti-Vascular Endothelial Growth Factor Therapeutics Market Through 2029?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10683

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.